Elion Hoxha

Elion Hoxha

Auto-generated profile, based on publicly available information

Elion Hoxha

Zentrum für Innere Medizin, lll. Medizinische Klinik, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2016 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
NTNicola M. Tomas
Nicola M. Tomas
EHElion Hoxha
Elion Hoxha
ARAnna T. Reinicke
Anna T. Reinicke
LFLars Fester
Lars Fester
UHUdo Helmchen
Udo Helmchen
RSRolf A.K. Stahl
Rolf A.K. Stahl
Membranous nephropathy (MN) is the most common cause of nephrotic syndrome in adults, and one-third of patients develop end-stage renal disease (ESRD). Circulating autoantibodies against the podocyte surface antigens phospholipase A2 receptor 1 (PLA2R1) and the recently identified thrombospondin type 1 domain–containing 7A (THSD7A) are assumed to cause the disease in the majority of patients. The pathogenicity of these antibodies, however, has not been directly proven. Here, we have reported the analysis and characterization of a male patient with THSD7A-associated MN who progressed to ESRD and subsequently underwent renal transplantation. MN rapidly recurred after transplantation. Enhanced staining for THSD7A was observed in the kidney allograft, and detectable anti-THSD7A antibodies were present in the serum before and after transplantation, suggesting that these antibodies induced a recurrence of MN in the renal transplant. In contrast to PLA2R1, THSD7A was expressed on both human and murine podocytes, enabling the evaluation of whether anti-THSD7A antibodies cause MN in mice. We demonstrated that human anti-THSD7A antibodies specifically bind to murine THSD7A on podocyte foot processes, induce proteinuria, and initiate a histopathological pattern that is typical of MN. Furthermore, anti-THSD7A antibodies induced marked cytoskeletal rearrangement in primary murine glomerular epithelial cells as well as in human embryonic kidney 293 cells. Our findings support a causative role of anti-THSD7A antibodies in the development of MN.

12 March 2024 in Circulation
Verified
Journal Article
Open access
ABAnja M. Billing
Anja M. Billing
YKYoung Chul Kim
Young Chul Kim
SGSøren Gullaksen
Søren Gullaksen
BSBenedikt Schrage
Benedikt Schrage
JRJanice Raabe
Janice Raabe
MRMarkus M. Rinschen
Markus M. Rinschen
BACKGROUND: SGLT2 (sodium-glucose cotransporter 2) inhibitors (SGLT2i) can protect the kidneys and heart, but the underlying mechanism remains poorly understood. METHODS: To gain insights on primary effects of SGLT2i that are not confounded by pathophysiologic processes or are secondary to improvement by SGLT2i, we performed an in-depth proteomics, phosphoproteomics, and metabolomics analysis by integrating signatures from multiple metabolic organs and body fluids after 1 week of SGLT2i treatment of nondiabetic as well as diabetic mice with early and uncomplicated hyperglycemia. RESULTS: Kidneys of nondiabetic mice reacted most strongly to SGLT2i in terms of proteomic reconfiguration, including evidence for less early proximal tubule glucotoxicity and a broad downregulation of the apical uptake transport machinery (including sodium, glucose, urate, purine bases, and amino acids), supported by mouse and human SGLT2 interactome studies. SGLT2i affected heart and liver signaling, but more reactive organs included the white adipose tissue, showing more lipolysis, and, particularly, the gut microbiome, with a lower relative abundance of bacteria taxa capable of fermenting phenylalanine and tryptophan to cardiovascular uremic toxins, resulting in lower plasma levels of these compounds (including p-cresol sulfate). SGLT2i was detectable in murine stool samples and its addition to human stool microbiota fermentation recapitulated some murine microbiome findings, suggesting direct inhibition of fermentation of aromatic amino acids and tryptophan. In mice lacking SGLT2 and in patients with decompensated heart failure or diabetes, the SGLT2i likewise reduced circulating p-cresol sulfate, and p-cresol impaired contractility and rhythm in human induced pluripotent stem cell–derived engineered heart tissue. CONCLUSIONS: SGLT2i reduced microbiome formation of uremic toxins such as p-cresol sulfate and thereby their body exposure and need for renal detoxification, which, combined with direct kidney effects of SGLT2i, including less proximal tubule glucotoxicity and a broad downregulation of apical transporters (including sodium, amino acid, and urate uptake), provides a metabolic foundation for kidney and cardiovascular protection.

8 April 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
MZMarina Zimmermann
Marina Zimmermann
MKMartin Klaus
Martin Klaus
MWMilagros N. Wong
Milagros N. Wong
ATAnn-Katrin Thebille
Ann-Katrin Thebille
LGLukas Gernhold
Lukas Gernhold
VPVictor G. Puelles
Victor G. Puelles
Morphologic examination of tissue biopsies is essential for histopathological diagnosis. However, accurate and scalable cellular quantification in human samples remains challenging. Here, we present a deep learning–based approach for antigen-specific cellular morphometrics in human kidney biopsies, which combines indirect immunofluorescence imaging with U-Net–based architectures for image-to-image translation and dual segmentation tasks, achieving human-level accuracy. In the kidney, podocyte loss represents a hallmark of glomerular injury and can be estimated in diagnostic biopsies. Thus, we profiled over 27,000 podocytes from 110 human samples, including patients with antineutrophil cytoplasmic antibody–associated glomerulonephritis (ANCA-GN), an immune-mediated disease with aggressive glomerular damage and irreversible loss of kidney function. We identified previously unknown morphometric signatures of podocyte depletion in patients with ANCA-GN, which allowed patient classification and, in combination with routine clinical tools, showed potential for risk stratification. Our approach enables robust and scalable molecular morphometric analysis of human tissues, yielding deeper biological insights into the human kidney pathophysiology.

6 April 2021 in Cell and tissue research
Verified
Journal Article
Open access
PDF file
NTNicola M. Tomas
Nicola M. Tomas
THTobias B. Huber
Tobias B. Huber
EHElion Hoxha
Elion Hoxha
The identification of the phospholipase A2 receptor 1 (PLA2R) and thrombospondin type-1 domain-containing protein 7A (THSD7A) as podocyte antigens in adult patients with membranous nephropathy (MN) has strongly impacted both experimental and clinical research on this disease. Evidence has been furnished that podocyte-directed autoantibodies can cause MN, and novel PLA2R- and THSD7A-specific animal models have been developed. Today, measurement of serum autoantibody levels and staining of kidney biopsies for the target antigens guides MN diagnosis and treatment worldwide. Additionally, anti-PLA2R antibodies have been proven to be valuable prognostic biomarkers in MN. Despite these impressive advances, a variety of questions regarding the disease pathomechanisms, clinical use of antibody measurement, and future treatments remain unanswered. In this review, we will outline recent advances made in the field of MN and discuss open questions and perspectives with a focus on novel antigen identification, mechanisms of podocyte injury, clinical use of antibody measurement to guide diagnosis and treatment, and the potential of innovative, pathogenesis-based treatment strategies.

10 January 2023 in JCI Insight
Verified
Journal Article
Open access
PDF file
JRJan-Hendrik Riedel
Jan-Hendrik Riedel
LRLennart Robben
Lennart Robben
HPHans-Joachim Paust
Hans-Joachim Paust
YZYu Zhao
Yu Zhao
NANariaki Asada
Nariaki Asada
UPUlf Panzer
Ulf Panzer
Glucocorticoids remain a cornerstone of therapeutic regimes for autoimmune and chronic inflammatory diseases — for example, in different forms of crescentic glomerulonephritis — because of their rapid antiinflammatory effects, low cost, and wide availability. Despite their routine use for decades, the underlying cellular mechanisms by which steroids exert their therapeutic effects need to be fully elucidated. Here, we demonstrate that high-dose steroid treatment rapidly reduced the number of proinflammatory CXCR3 + CD4 + T cells in the kidney by combining high-dimensional single-cell and morphological analyses of kidney biopsies from patients with antineutrophil cytoplasmic antibody–associated (ANCA-associated) crescentic glomerulonephritis. Using an experimental model of crescentic glomerulonephritis, we show that the steroid-induced decrease in renal CD4 + T cells is a consequence of reduced T cell recruitment, which is associated with an ameliorated disease course. Mechanistic in vivo and in vitro studies revealed that steroids act directly on renal tissue cells, such as tubular epithelial cells, but not on T cells, which resulted in an abolished renal expression of CXCL9 and CXCL10 as well as in the prevention of CXCR3 + CD4 + T cell recruitment to the inflamed kidneys. Thus, we identified the CXCL9/CXCL10-CXCR3 axis as a previously unrecognized cellular and molecular target of glucocorticoids providing protection from immune-mediated pathology.

18 April 2021 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
JMJohannes Münch
Johannes Münch
BKBastian M. Krüger
Bastian M. Krüger
AWAntje Weimann
Antje Weimann
TWThorsten Wiech
Thorsten Wiech
LRLinda Reinhard
Linda Reinhard
JHJan Peter Halbritter
Jan Peter Halbritter
Membranous nephropathy (MN) constitutes a major cause of nephrotic syndrome in adults. After kidney transplantation (KTx), both recurrent and de‐novo MN has been reported. In addition to PLA2R and THSD7A, recent identification of neural EGFL‐like‐1 protein, NELL1, as a potential disease antigen has enriched our understanding of MN pathogenesis. To date, NELL1‐positive MN has only been described in native kidneys, but never been diagnosed in renal allografts. We here report on a 56 year‐old male kidney transplant recipient suffering from amyotrophic lateral sclerosis, who developed nephrotic syndrome 25 years after KTx. Allograft biopsy revealed NELL1‐positive MN. Using specifically established immunoblotting techniques, we detected new‐onset NELL1‐IgG1, IgG3, and IgG4 antibodies in the patient's serum correlating with the course of proteinuria. While primary renal disease was undetermined, MN recurrence seemed unlikely given the long‐time span since KTx. By clinical investigation of de‐novo etiologies, we did not detect an underlying malignancy. However, previous self‐medication with dimercaptopropane sulfonate and alpha lipoic acid represented a potential trigger and cessation associated with partial remission of proteinuria. This report illustrates the first case of post‐transplant nephrotic syndrome due to NELL1‐positive MN. Monitoring NELL1‐antibodies in the serum promise to be a non‐invasive diagnostic tool guiding disease management.